ERBB2 and aneurysmal bone cyst: Based on EMBRACA and OlympiAD studies, two PARPi: talazoparib and olaparib, respectively, obtained U.S. Food and Drug Administration approval for the treatment of gBRCA1/2m HER2 negative (HER2-ve) advanced breast cancer (ABC) [4, 5].